Zelluna Immunotherapy
Privately owned Norwegian biopharmaceutical company.
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | (19948 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | (20517 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on developing innovative cancer therapies using T cell receptors (TCRs) and natural killer (NK) cells. The company operates in the biopharmaceutical sector, targeting the oncology market, specifically solid tumors with high unmet medical needs. Zelluna's core product involves TCR-guided NK cell therapies, which combine the broad target range of TCRs with the potency and allogeneic nature of NK cells. This approach aims to create effective cell therapy products that can be supplied to treat patients with various solid cancers.
Zelluna collaborates with leading organizations, including an exclusive license agreement with the U.S. National Cancer Institute, to develop and commercialize therapies targeting specific cancer markers such as KK LC 1, MAGE A4, and VGLL1. The company's business model revolves around research and development, securing exclusive licenses, and forming strategic partnerships to advance its therapeutic platform. Revenue is generated through licensing agreements, collaborations, and potentially future commercialization of its therapies.
Keywords: TCR-guided, NK cells, solid tumors, biopharma, oncology, cancer therapy, exclusive licenses, strategic partnerships, innovative treatments, high unmet medical need.